NeuroPace

NeuroPace's mission is to transform the lives of people suffering from drug-resistant epilepsy through its innovative, data-driven neuromodulation platform. Its core achievement is the 2013 FDA approval and subsequent commercialization of the RNS System, a first-in-class responsive neurostimulator that has treated thousands of patients. The company's strategy is to deepen its penetration in the focal epilepsy market, expand into new neurological indications, and leverage its proprietary brain data platform to establish a new standard of care in personalized neuromodulation.

The RNS® System is a closed-loop, brain-responsive neuromodulation platform that continuously monitors brain activity (ECoG), detects personalized seizure onset patterns, and delivers targeted electrical stimulation to abort seizures, while recording chronic brain data for clinical optimization.

NeuroPace competes primarily with open-loop neuromodulation devices (LivaNova's VNS, Medtronic's DBS) and surgical procedures (resection, ablation). Its key differentiators are its closed-loop, responsive therapy and chronic brain data recording, positioning it as a more advanced, personalized option for well-localized, drug-resistant epilepsy.